Skip to content

Aquestive Therapeutics

US · AQST #3650 by market cap Listed 2018
3.46 -0.25 -6.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.6 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
57.49% -0.56pp
Institutions
208 -1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund34.08%
Hedge Fund12.75%
Public Company4.30%
Individual/Insider4.04%
VC/PE Fund2.74%
Private Company2.28%
Insurance Company0.79%
Family Office/Trust0.34%
Government Pension Fund0.21%
Other38.47%

Top holders as of 2026-09-30

BlackRock 6.53% · 8.21M sh
Bratton Capital Management, L.P. 7.82% · 9.81M sh
Thru Line L.P. 6.27% · 7.88M sh
RTW Investments, LP 5.91% · 7.43M sh
Vanguard Capital Management, LLC 3.81% · 4.78M sh
State Street Global Advisors 2.77% · 3.48M sh
Federated Hermes, Inc. 2.54% · 3.20M sh
Geode Capital Management, LLC 2.30% · 2.90M sh
Samsara BioCapital LLC 1.99% · 2.50M sh
Bank of America Corporation 1.33% · 1.67M sh
Edward Bass 1.20% · 1.51M sh
Sio Capital Management, LLC 1.18% · 1.49M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 22 buys · 26 sells

NameRoleStake
Daniel Barber Chief Executive Officer 0.50%
Stephen Wargacki Former Chief Science Officer 0.27%
Peter Boyd Senior Vice President of Information Technology & Chief People Officer 0.23%
A. Toth Senior Vice President 0.23%
Carl Kraus Former Chief Medical Officer 0.22%
Melina Cioffi Senior Vice President of Regulatory Affairs 0.22%
Douglas Bratton Former Independent Director 0.20%
Sherry Korczynski Chief Commercial Officer 0.19%
Lori Braender Corporate Secretary 0.18%
Cassie Jung Chief Operating Officer 0.17%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Richard John Daly Independent Director Open Market Acquisition +28,025 $3.53–3.55
2026-11-09 Matthew Davis Chief Development Officer Sale to Issuer -5,303 $3.52
2026-11-05 Richard John Daly Independent Director Other Derivative Acquisition +57,000 $3.61
2026-10-20 John Cochran Independent Vice Chairperson Other Acquisition +62,229 --
2026-10-14 Richard John Daly Independent Director Initial Statement of Beneficial 0 --
2026-10-14 Daniel Barber Chief Executive Officer Open Market Disposition -25,000 $4.22
2026-09-14 Daniel Barber Chief Executive Officer Open Market Disposition -25,000 $4.82
2026-09-08 Peter Boyd Senior Vice President of Information Technology & Chief People Officer Derivative Exercise and Retained +2,293 $0.96
2026-09-08 Sherry Korczynski Chief Commercial Officer Derivative Exercise and Sale -8,750 $2.65–5.22
2026-09-07 Daniel Barber Chief Executive Officer Derivative Exercise and Retained +91,743 $0.96
2026-09-02 Cassie Jung Chief Operating Officer Derivative Exercise and Retained +4,587 $0.96
2026-08-16 Daniel Barber Chief Executive Officer Open Market Disposition -25,000 $4.29
2026-08-13 Sherry Korczynski Chief Commercial Officer Sale to Issuer -2,714 $4.25
2026-07-15 Daniel Barber Chief Executive Officer Open Market Disposition -25,000 $4.00–4.03
2026-07-14 Daniel Barber Chief Executive Officer Intent to Sell (Form 144) -25,000 $4.04
2026-06-22 Julie Krop Independent Director Derivative Exercise and Sale -25,000 $0.71–5.02
2026-06-14 Daniel Barber Chief Executive Officer Open Market Disposition -25,000 $4.16
2026-06-09 Timothy Morris Independent Director Other Derivative Acquisition +50,500 $3.99
2026-06-09 Gregory Brown Independent Chairperson Other Derivative Acquisition +50,500 $3.99
2026-06-09 Julie Krop Independent Director Other Derivative Acquisition +50,500 $3.99

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Aquestive Therapeutics discussion 0 comments

Add a comment